Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M119Revenue (TTM) $M136Net Margin (%)25.7Altman Z-Score-1.4
Enterprise Value $M103EPS (TTM) $0.3Operating Margin %49.6Piotroski F-Score7
P/E(ttm)3.4Beneish M-Score-2.3Pre-tax Margin (%)25.7Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %--Quick Ratio7.7Cash flow > EarningsY
Price/Sales0.95-y EBITDA Growth Rate %--Current Ratio8.1Lower Leverage y-yN
Price/Free Cash Flow2.7y-y EBITDA Growth Rate %--ROA % (ttm)12.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VVUS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VVUS is held by these investors:



VVUS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Varghese Santosh TChief Medical Officer 2017-04-04Sell440$1.084.63view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-10Sell1,149,400$1.16-2.59view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-07Sell192,800$1.084.63view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-02Sell160,100$1.130view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-27Sell333,000$1.14-0.88view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-22Sell161,800$1.111.8view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-16Sell305,090$1.12.73view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-13Sell176,410$1.111.8view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-08Sell563,527$1.066.6view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-03Sell78,633$1.120.89view

Press Releases about VVUS :

Quarterly/Annual Reports about VVUS:

News about VVUS:

Articles On GuruFocus.com
VIVUS to Extend Return Date of STENDRA Commercial Rights Jun 30 2016 
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference Apr 19 2016 
Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
5-year lows: PICO Holdings Inc, Black Box Corp, Vivus, and Electro Rent Corp. Mar 29 2015 
A Look at Pharma Company Dermira's Performance Mar 27 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS Mar 25 2014 
Billionaires Hold Four Stocks, 59% Off Sep 30 2013 
Unique Investor Kyle Bass Unloads Five May 29 2013 

More From Other Websites
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet May 26 2017
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data May 26 2017
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 May 26 2017
Aerie's Ophthalmic Candidate Positive in Registration Trial May 25 2017
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer May 25 2017
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session May 25 2017
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair May 25 2017
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler May 25 2017
Thomas B. King Joins VIVUS' Board of Directors May 24 2017
Achaogen's Plazomicin Gets Breakthrough Therapy Designation May 24 2017
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio May 24 2017
Theravance/Mylan Presents Phase III Data on COPD Candidate May 24 2017
Ultragenyx Receives Priority Review for rhGUS from FDA May 24 2017
BioLineRx Makes Regulatory Submission for Trial of BL-8040 May 23 2017
Merck Presents Phase II Data on Chronic Cough Candidate May 23 2017
Roche's Arthritis Drug Gets FDA Nod for Label Expansion May 23 2017
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint May 23 2017
Catalyst Pharmaceuticals Focuses on Development of Firdapse May 23 2017
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study May 23 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)